Adverse left ventricular remodeling by glycoprotein nonmetastatic melanoma protein B in myocardial infarction

Anne Järve1,2, Silke Mühlstedt1,3,4, Fatimunnisa Qadri1

  • 1Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Insights

Glycoprotein nonmetastatic melanoma protein B (GPNMB) worsens heart damage after myocardial infarction. Reducing GPNMB levels protected cardiac function and reduced adverse remodeling in mouse models, highlighting GPNMB as a potential therapeutic target.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Pathology

Background:

  • Cardiac diseases are a leading cause of mortality globally.
  • Current treatments for myocardial infarction (MI) cannot fully reverse cardiac damage.
  • Identifying novel therapeutic targets for cardiac injury is crucial.

Purpose of the Study:

  • To investigate the role of glycoprotein nonmetastatic melanoma protein B (GPNMB) in cardiac remodeling after myocardial infarction (MI).
  • To determine if GPNMB influences cardiac function and adverse structural changes post-MI.

Main Methods:

  • Microarray screening identified GPNMB in rat hearts post-MI.
  • Cardiac GPNMB expression was analyzed in rat and mouse models of MI.
  • GPNMB deficiency effects were studied in DBA/2J mice and muscle lim protein knockout mice.

Main Results:

  • Cardiac GPNMB expression increased after MI in rodents.
  • GPNMB deficiency preserved cardiac function and reduced left ventricular dilation post-MI.
  • GPNMB deficiency decreased matrix metalloproteinase 9 and cardiac stress gene expression.

Conclusions:

  • GPNMB plays an adverse role in myocardial remodeling following ischemic injury.
  • Targeting GPNMB may offer a novel therapeutic strategy for mitigating cardiac damage after MI.
  • GPNMB deficiency attenuated dilated cardiomyopathy but not pressure-overload hypertrophy.